贝伐珠单抗联合奥沙利铂和卡培他滨治疗晚期结直肠癌的临床疗效分析

Analysis of Clinical Efficacy of Bevacizumab Combined with Oxaliplatin and Capecitabine in the Treatment of Advanced Colorectal Cancer

目的探讨贝伐珠单抗联合奥沙利铂和卡培他滨治疗晚期结直肠癌的临床疗效。方法随机选取该院2019年1月—2020年1月收治的晚期结直肠患者60例作为研究对象,通过掷骰子法分为对照组和研究组。对照组(n=32)采用奥沙利铂静脉滴注治疗,研究组(n=28)在此基础上联合7.5 mg/kg贝伐单抗静脉滴注治疗。比较两组患者的临床疗效、短期生存率、不良反应发生率、血清因子水平及Karnofsky评分差异。结果研究组治疗有效率为85.71%(24/28)显著高于对照组56.25%(18/32),差异有统计学意义(χ^(2)=6.173,P<0.05);研究组患者的1年和2年生存率分别为92.86%、75.00%均显著高于对照组71.88%、50.00%,差异有统计学意义(χ^(2)=4.391、3.948,P<0.05);治疗后,两组患者血清CEA、CA199、CA125水平均显著下降,KPS评分提高,研究组的变化幅度均明显大于对照组,差异有统计学意义(t=6.546、5.729、5.050、6.659,P<0.05);两组患者的各类药物相关不良反应发生率数据差异无统计学意义(P>0.05)。结论贝伐珠单抗联合奥沙利铂和卡培他滨治疗对晚期结直肠癌的疗效确切,可显著延长患者的短期生存率,降低其血清CEA、CA199、CA125水平,改善功能状况,安全可靠。

Objective To investigate the clinical efficacy of bevacizumab combined with oxaliplatin and capecitabine in the treatment of advanced colorectal cancer.Methods A total of 60 advanced colorectal patients admitted to the hospital from January 2019 to January 2020 were randomly selected as the research objects.They were divided into a control group and a study group by rolling the dice.The control group(n=32)was treated with oxaliplatin intravenous infusion,and the study group(n=28)was combined with 7.5 mg/kg bevacizumab intravenous infusion on this basis.The clinical efficacy,short-term survival rate,incidence of adverse reactions,serum factor levels and Karnofsky scores were compared between the two groups of patients.Results The effective rate of treatment in the study group was 85.71%(24/28)significantly higher than 56.25%(18/32)in the control group,the difference was statistically significant(χ^(2)=6.173,P<0.05);1 year and 2 years for patients in the study group of the survival rates of 92.86%and 75.00%were significantly higher than those of the control group 71.88%and 50.00%,and the difference was statistically significant(χ^(2)=4.391,3.948,P<0.05);after treatment,the serum CEA,CA199,and CA125 levels of the two groups were significantly decreased,and the KPS score changes in the study group were significantly greater than those in the control group,and the difference was statistically significant(t=6.546,5.729,5.050,6.659,P<0.05);there was no statistically significant difference in the incidence of various drug-related adverse reactions between the two groups of patients(P>0.05).Conclusion Bevacizumab combined with oxaliplatin and capecitabine has a definite effect on advanced colorectal cancer and can significantly prolong the short-term survival rate of patients.Reduce its serum CEA,CA199,CA125 levels,improve functional status,safe and reliable.